Clinical trial
A Phase Ib, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of Volitinib in Combination With Gefitinib in Patients With Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer Who Have Progressed on Epidermal Growth Factor Receptor Inhibitor Treatment
NCT02374645 is registered in ClinicalTrials.gov with Hutchison Medipharma Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of Volitinib in Combination With Gefitinib in Patients With Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer Who Have Progressed on Epidermal Growth Factor Receptor Inhibitor Treatment
- Lead sponsor
- Hutchison Medipharma Limited
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 30, 2015
- Completion date
- September 14, 2018
- Enrollment
- 64 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-small cell lung cancer